ALR Technologies Moves to Acquire CGM Medical in $45 Million Deal

CEO Sidney Chan described the move as a transition into a fully integrated diabetes company, granting ALR full control over intellectual property and manufacturing margins. The acquisition involves two distinct phases: purchasing the Singapore-based technology firm for 200 million shares and a $40 million promissory note, and acquiring the Shenzhen-based assets for up to $5 million in cash.

Financial obligations for the $40 million note are tied to future performance, specifically triggered once a planned facility in the Johor-Singapore Special Economic Zone reaches a production capacity of 500,000 units per month. At that point, ALR will allocate 25% of its free cash flow to settle the debt. A similar cash-flow-based payout structure applies to the Shenzhen component, which focuses on production at the InnoMax facility. ALR is currently investing $1.65 million in automation equipment there to boost capacity to 300,000 units monthly.

Completion of the transactions remains subject to definitive agreements, regulatory approvals, and due diligence. The company expects to finalize the Singapore acquisition by August 31, 2026, followed by the Shenzhen deal in early 2027. This integration builds on the existing partnership between the two companies, which successfully launched the GluCurve Pet CGM, a specialized monitoring system for cats and dogs, in May 2026.